All In Biotech

Drug Trial Radar · NCT05275998

TMB-365 and TMB-380 in Suppressed HIV-1 Infected Individuals

A Phase 1b/2 Dose Escalation Study of the Safety, Pharmacokinetics, and Efficacy of the Combination of TMB-365 and TMB-380 in HIV-1 Infected Individuals Suppressed With Combination Antiretroviral Therapy

Last checked: Nov 19, 2026Latest source record: Oct 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

51

Actual

Start

Jul 5, 2022

Primary completion

Nov 20, 2024

Study completion Nov 20, 2024

Sponsor

Lead sponsor
TaiMed Biologics Inc.Industry
Sponsor type
Industry
First posted
Mar 11, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

TMB-365 is a monoclonal antibody that binds to the CD4 receptor. TMB-380, aka VRC-07-523LS is a monoclonal antibody that binds to HIV. Both interfere with HIV entry. This study is designed to test various doses of the combination of the antibodies for safety and pharmacokinetics in suppressed subjects on cART. Once dosing is established based on safety and PK, the optimally dosed combinations will be assessed as maintenance therapy in HIV infected suppressed individuals discontinuing oral cART for 24 weeks.

Conditions

  • HIV-1-infection

Interventions

  • TMB-365/TMB-380Drug

    Monoclonal antibodies to be given intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety of TMB-365 and TMB-380 Given Intravenously (Sentinel and Core)Time frame: 12 weeks (Sentinel Group 1), 16 weeks (Sentinel Group 2, 3), 28 weeks (Core Group)
  2. Pharmacokinetics of a Single Dose TMB-365 Given Intravenously (Sentinel)Time frame: Week 8
  3. Pharmacokinetics of TMB-365 Given Intravenously Every 8 Weeks (Core)Time frame: Week 8, 16, and 24
  4. Pharmacokinetics of a Single Dose TMB-380 Given Intravenously (Sentinel)Time frame: Week 8
  5. Pharmacokinetics of TMB-380 Given Intravenously Every 8 Weeks (Core)Time frame: Weeks 8, 16, and 24
  6. Antiviral Activity of the Combination of TMB-365 in Combination With TMB-380 as Maintenance Therapy (Core)Time frame: Week 24

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Quest Clinical Research

    San Francisco, California

  • CAN Community Health

    Fort Lauderdale, Florida

  • Midway Immunology and Research Center

    Ft. Pierce, Florida

  • Orlando Immunology Center

    Orlando, Florida

  • North Texas Infectious Disease Consultants

    Dallas, Texas

  • Crofoot Research Center, Inc.

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.